Want to see AU:CYP full AI Analyst Report?
Top Page
Cynata Therapeutics Limited
(Sydney:CYP)
Select Model
Select Model
Rating:41Neutral
Price Target:
AU$0.01
â–²(10.00% Upside)
Action:Upgraded
Date:10/09/26
Overall score is low, driven primarily by weak financial performance (persistent losses, ongoing cash burn, and equity turning negative) and bearish technical trends (price well below long-term moving averages and negative MACD). Valuation provides limited support due to negative earnings and no indicated dividend yield.
Positive Factors
No Debt
Zero debt reduces interest obligations and refinancing exposure, giving the company greater financial flexibility than a similarly loss-making business with leverage. This can preserve strategic options while management develops clinical programs, although it does not remove the need for funding.
Negative Factors
Persistent Losses
Persistent losses remain a fundamental weakness because the company is not yet converting its development activities into sustainable earnings. The 2026 loss was large relative to revenue, limiting internally generated capital and increasing the importance of successful clinical progress or commercial partnerships.
Read all positive and negative factors
Positive Factors
Negative Factors
No Debt
Zero debt reduces interest obligations and refinancing exposure, giving the company greater financial flexibility than a similarly loss-making business with leverage. This can preserve strategic options while management develops clinical programs, although it does not remove the need for funding.
Read all positive factors
Cynata Therapeutics Limited (CYP) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$2.68M
Dividend YieldN/A
Average Volume (3M)375.31K
Price to Earnings (P/E)―
Beta (1Y)0.95
Revenue GrowthN/A
EPS Growth13.50%
CountryAU
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.04
Shares Outstanding243,454,380
10 Day Avg. Volume290,663
30 Day Avg. Volume375,308
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-8.41
Price to Sales (P/S)1.94
P/FCF Ratio-0.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)AU$31.40M
Cynata Therapeutics Limited Business Overview & Revenue Model
Company Description
Headquartered in Cremorne, Australia, Cynata Therapeutics Limited, established in 2003 and formerly known as Eco Quest Limited until its 2013 rebranding, specializes in the development and commercialization of its proprietary Cymerus mesenchymal s...
How the Company Makes Money
Cynata’s ability to generate revenue is primarily tied to the development and commercialization of its cell-therapy candidates rather than ongoing product sales. Its main potential and/or historical revenue streams are: (1) collaboration and licen...
Cynata Therapeutics Limited Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
34
Negative
Cash Flow
22
Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.71M | 1.89M | 2.32M | 1.65M | 7.77M |
| Gross Profit | -260.31K | 1.89M | 2.32M | 1.37M | 7.49M |
| EBITDA | -7.55M | -9.33M | -9.95M | -15.65M | -6.00M |
| Net Income | -9.09M | -9.39M | -9.74M | -14.28M | -5.45M |
Balance Sheet | |||||
| Total Assets | 1.35M | 7.20M | 8.39M | 18.99M | 26.55M |
| Cash, Cash Equivalents and Short-Term Investments | 897.42K | 5.05M | 6.21M | 16.17M | 23.80M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 1.75M | 1.22M | 1.17M | 2.26M | 2.59M |
| Stockholders Equity | -394.24K | 5.98M | 7.22M | 16.73M | 23.96M |
Cash Flow | |||||
| Free Cash Flow | -6.74M | -8.77M | -9.96M | -14.28M | -3.30M |
| Operating Cash Flow | -6.74M | -8.72M | -9.96M | -14.28M | -3.30M |
| Investing Cash Flow | 0.00 | -50.00K | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 2.58M | 7.61M | 0.00 | 6.72M | 210.12K |
Cynata Therapeutics Limited Technical Analysis
Positive
0.01
Price Trends
0.01
Positive
0.06
Negative
0.20
Negative
Market Momentum
>-0.01
Negative
52.73
Neutral
22.22
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:CYP, the sentiment is Positive. The current price of 0.01 is below the 20-day moving average (MA) of 0.01, below the 50-day MA of 0.01, and below the 200-day MA of 0.20, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 52.73 is Neutral, neither overbought nor oversold. The STOCH value of 22.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:CYP.
Cynata Therapeutics Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | AU$2.59B | -31.12 | -10.06% | ― | 555.67% | 49.08% | |
52 Neutral | AU$15.89M | -2.14 | -247.44% | ― | -4.24% | 33.39% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | AU$193.40M | -13.11 | -36.83% | ― | 51.07% | -47.63% | |
43 Neutral | AU$5.14M | -0.96 | -52.04% | ― | 32.22% | -26.53% | |
41 Neutral | AU$2.68M | -0.39 | -607.23% | ― | ― | 13.50% | |
40 Underperform | AU$18.25M | -5.00 | -132.20% | ― | ― | -200.00% |
* Healthcare Sector Average
AU:CYP
Cynata Therapeutics Limited
0.01
-0.22
-94.78%
AU:1AI
Living Cell Technologies
0.01
0.00
0.00%
AU:MSB
Mesoblast Limited
1.94
-0.96
-33.04%
AU:OCC
Orthocell Ltd
0.70
-0.84
-54.58%
AU:TRP
Tissue Repair Ltd
0.09
-0.18
-67.31%
AU:CMB
Regeneus Ltd.
0.54
0.06
11.34%
Cynata Therapeutics Limited Corporate Events
Cynata defines target market for new options in capital raising
Oct 7, 2026
Cynata Therapeutics has issued a target market determination for new options over its ordinary shares, linked to a 3-for-8 pro rata renounceable entitlement offer and associated shortfall and underwriting arrangements. The options, which are unquo...
Cynata Therapeutics Launches Renounceable Entitlement Offer to Raise Capital
Oct 7, 2026
Cynata Therapeutics has launched a non-accelerated, renounceable pro rata entitlement offer, allowing eligible shareholders to subscribe for 3 new shares for every 8 held at $0.01 per share, with one free attaching option for every 3 new shares, t...
Cynata Plans Issue of 18 Million Options to Support Capital Needs
Oct 7, 2026
Cynata Therapeutics Limited has notified the ASX of a proposed issue of new securities in the form of options. The company plans to issue up to 18,000,000 options, exercisable at $0.02 and expiring on May 3, 2029, with a proposed issue date of Nov...
Cynata Therapeutics Launches Major Renounceable Pro Rata Offer
Oct 7, 2026
Cynata Therapeutics has announced a renounceable pro rata offer to issue up to 91,295,388 new ordinary fully paid shares and 30,431,796 options exercisable at $0.02 and expiring on 3 May 2029. The offer, with key dates in October and an issue date...
Cynata launches discounted entitlement offer to fund strategic review
Oct 7, 2026
Cynata Therapeutics has launched a fully underwritten, three-for-eight renounceable entitlement offer to raise about $913,000, with new shares priced at $0.01, a 9.1% discount to the prior ASX close, and accompanied by free attaching options exerc...
Cynata Ends Equity Facility With Acuity, Plans Buyback of Security Shares
Oct 7, 2026
Cynata Therapeutics has moved to terminate its At-the-Market Subscription Deed with Acuity Capital, which had provided up to $7.5 million in standby equity capital, effective 14 October 2026. The company previously raised $1.204 million under this...
Cynata Uses $1.7m R&D Refund to Clear Loan and Bolster Cymerus Strategy
Oct 7, 2026
Cynata Therapeutics has received a Research and Development Tax Incentive refund of $1.694 million from the Australian Government for the 2025/2026 financial year, reflecting ongoing investment in its Cymerus mesenchymal stromal cell technology. T...
Cynata Extends R&D Tax Incentive Loan Ahead of $1.7m Rebate
Sep 30, 2026
Cynata Therapeutics Limited has secured an extension of the maturity date on its $600,000 Research and Development Tax Incentive loan facility from 30 September 2026 to 30 November 2026, under an agreement with its commercial lender. The facility ...
Cynata Updates Corporate Governance Framework to Strengthen Board Oversight
Sep 28, 2026
Cynata Therapeutics has released an updated Corporate Governance Statement outlining how its board manages and oversees the company in line with the ASX Corporate Governance Principles and Recommendations. The statement details a clear separation ...
Cynata Releases 2025/2026 Annual Report and Confirms Corporate Structure
Sep 28, 2026
Cynata Therapeutics Limited has released its annual report for the financial year ended 30 June 2026, outlining its corporate structure and governance arrangements. The report details the company’s registered office, board composition, audit...
Cynata Adjusts 2026 Results After GvHD Trial Close-Out Accrual
Sep 24, 2026
Cynata Therapeutics has revised its audited financial results for the year ended 30 June 2026 following the completion of its audit, recognising an additional accrual related to its Phase 2 clinical trial of CYP-001 in acute graft-versus-host dise...
Cynata Options Lapse, Streamlining ASX-Listed Capital Structure
Sep 10, 2026
Cynata Therapeutics Limited has updated the market on changes to its capital structure following the expiry of several tranches of listed options. On 10 September 2026, a total of 3 million options with exercise prices ranging from $0.40 to $0.60 ...
Cynata narrows loss but trial setbacks and cash squeeze deepen going-concern risk
Aug 31, 2026
Cynata Therapeutics reported a net loss of $9.1 million for the year to 30 June 2026, slightly improved from the prior year, as revenues fell and cash reserves dropped to $0.9 million. The group moved from net assets to net liabilities and recorde...
Cynata Plans ASX-Quoted Share Placement to Raise Capital
Aug 25, 2026
Cynata Therapeutics Limited has notified the ASX of a proposed issue of up to 2,000,000 ordinary fully paid shares. The placement, scheduled for issue on 30 October 2026, is intended to be quoted on the ASX in line with listing rule requirements, ...
Cynata Slashes Costs After Key Cell Therapy Trials Miss Efficacy Targets
Jul 30, 2026
Cynata Therapeutics reported June quarter results marked by disappointing efficacy outcomes in two key Cymerus-based cell therapy programs, despite acceptable safety profiles. The Phase 2 trial of CYP-001 in high-risk acute graft versus host disea...
Cynata Options Lapse Clarifies Future Equity Structure
Jul 9, 2026
Cynata Therapeutics Limited has notified the market of the cessation of 24,445 options (CYPAE) expiring on November 20, 2028, exercisable at $0.185. These securities lapsed because the conditions attached to the options were not met or became inca...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.